A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

NCT01357993 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

253

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit / Hyperactivity Disorder

Interventions

DRUG: JNS001

Sponsor

Janssen Pharmaceutical K.K.